HANCOOK, Md., July 19, 2016 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTCQB:PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today announces it has retained Invicto Group, a leading investors relations and strategic advisory firm.
Dr. Ralph T. Salvagno, CEO of Petlife Pharmaceuticals noted, “Petlife is poised to change the paradigm of treatment in veterinary oncology. It is reported that over 50% of dogs and cats living past the age of 10 develop cancer meaning that approximately 13 million families yearly have to face this diagnosis in their beloved companion animals. Our all natural Escozine for Pets™ has a strong scientific basis for the treatment of cancer and offers an alternative to standard chemotherapy, surgery and other invasive treatment that are often as toxic as the cancer itself. Petlife’s mission is to provide an affordable solution that also avoids the unfortunate and often deadly side effects of traditional treatment. We hope to soon announce our Investigational New Drug Application seeking FDA approval for our technology and will also work to develop a daily nutraceutical preventive formulation. We are excited to be working with Invicto Group to assist in our efforts to bring this breakthrough drug to market.”
“After completing our due diligence of the company and its products we look forward to introducing PetLife Pharmaceuticals to the financial and investment community. In addition, we will look to reach out to the over 92 million pet owners in the U.S. and millions more around the world,” said Invicto Group.
About PetLife Pharmaceuticals, Inc.
PetLife Pharmaceuticals (OTCQB:PTLF) (www.PetLifePharma.com) is a registered US Veterinary Pharmaceutical company, incorporated in 2012.
PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets — Escozine for Pets™. It is based on the same patented ‘Escozine for Humans’ formula that has been sold by affiliated companies worldwide in 40 countries. Escozine for Pets™ uses a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.
PetLife’s mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology — with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications.
About Invicto Group
The Invicto Group team brings decades of collective experience, a vast range of expertise to provide investor relations, financial marketing, and advisory services to help public companies in the small-cap and micro-cap market to increase investor awareness and bring value to shareholders. There are many small-cap and micro-cap companies with top management and high growth potential that have difficulty in conveying their unique opportunity to the right Investors. In a profession that is increasingly complex and regulated, our approach is grounded in purpose and professionalism, backed by thinking that is fresh and creative.
Safe Harbor
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company’s business prospects and performance. The Company’s actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the Company’s filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.
CONTACT: Investor Relations: Invicto Group info@invictogroup.com 800-928-7462 Ext. 801
